Kathleen Guindon's Colleagues at QED Therapeutics
Kathleen Guindon's Contact Details
HQ
650-231-4088
650-231-4088
Location
Buffalo, New York
Buffalo, New York
Company
QED Therapeutics
QED Therapeutics
Kathleen Guindon's Company Details
QED Therapeutics, a subsidiary of BridgeBio Pharma, is a biotechnology company focused on precision medicine for FGFR-driven disorders. Our lead candidate is infigratinib, a best-in-class FGFR kinase inhibitor that has shown meaningful clinical activity in chemotherapy-refractory cholangiocarcinoma with FGFR2 fusions. QED is also evaluating infigratinib in preclinical studies for the treatment of achondroplasia. We plan to develop infigratinib in additional FGFR-driven tumor types and rare disorders.
Frequently Asked Questions about Kathleen Guindon
Kathleen Guindon currently works for QED Therapeutics.
Kathleen Guindon's role at QED Therapeutics is Sr. Director, MSL Team.
Kathleen Guindon's email address is ***@qedtx.com. To view Kathleen Guindon's full email address, please signup to ConnectPlex.
Kathleen Guindon works in the BioTech/Drugs industry.
Kathleen Guindon's colleagues at QED Therapeutics are Brian Boyles, Richard Jones II, Edward Oliva, Sudesh PhD, Quoc M., Ai Li, Craig Berman and others.
Kathleen Guindon's phone number is 650-231-4088